Oncorus
450 Kendall Street
4th Floor
Cambridge
Massachusetts
02142
United States
Tel: 857-320-6402
Website: http://www.oncorus.com/
Email: info@oncorus.com
About Oncorus
Oncorus is an early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world.YEAR FOUNDED:
April 2015
LEADERSHIP:
CEO: Mitchell H. Finer, Ph.D.
COO: Thomas W. Chalberg, Ph.D.
67 articles with Oncorus
-
Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
3/24/2023
Oncorus, Inc. today reported fourth quarter and full year 2022 financial results and provided an update on its business.
-
Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates
1/4/2023
Oncorus, Inc. and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620), a leading South Korean pharmaceutical company, today announced a research collaboration for the discovery and development of novel lipid nanoparticle (LNP) formulations for mRNA drug candidates.
-
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
11/30/2022
Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing IV administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that it is reprioritizing its pipeline to focus on its lead viral RNA (vRNA) immunotherapy product candidate, ONCR-021.
-
Oncorus to Participate in Upcoming Investor Conferences
11/23/2022
Oncorus, Inc.today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming investor conferences.
-
Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting
11/18/2022
Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced the presentation of preclinical data for ONCR-719 in a poster at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting, taking place November 17-20, 2022 in Tampa, Florida.
-
Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates
11/2/2022
Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, reported financial results for the third quarter of 2022 and highlighted recent achievements and developments.
-
Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer
10/7/2022
Oncorus, Inc. (Nasdaq: ONCR) today announced the publication of preclinical data in Nature Communications highlighting the potential of its synthetic viral RNA (vRNA)/lipid nanoparticle (LNP) platform as a novel approach to treating cancer by enabling repeat intravenous (IV) administration of viral immunotherapy.
-
Oncorus Appoints Douglas Fambrough to Board of Directors
6/23/2022
Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Douglas M. Fambrough, III, Ph.D. to its board of directors.
-
Oncorus to Present at the Jefferies Global Healthcare Conference - June 01, 2022
6/1/2022
Oncorus, Inc. announced that President and Chief Executive Officer, Theodore Ashburn, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 8, 2022 at 3:30 p.m. ET in New York, NY.
-
Oncorus to Present at the H.C. Wainwright Global Investment Conference
5/17/2022
Oncorus, Inc. announced that President and Chief Executive Officer, Theodore Ashburn, M.D., Ph.D., will present an update on the Company’s progress at the H.C. Wainwright Global Investment Conference.
-
Life sciences and biopharma companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Oncorus Announces Appointment of Richard Wanstall as Chief Financial Officer
5/10/2022
Oncorus, Inc., a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, announced the appointment of Richard Wanstall as Chief Financial Officer.
-
Oncorus Reports First Quarter 2022 Financial Results and Provides Business Updates
5/4/2022
Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today reported first quarter 2022 financial results and highlighted recent achievements and developments.
-
Oncorus Announces Debt Capital Facility with K2 HealthVentures with $20 Million Funded at Closing, Relocation of Corporate Headquarters and Extension of Cash Runway
4/5/2022
Oncorus, Inc. announced that it has entered into a loan and security agreement with K2 HealthVentures, a healthcare focused specialty finance company.
-
Oncorus to Present at the Maxim Group 2022 Virtual Growth Conference
3/21/2022
Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced that President and Chief Executive Officer, Theodore Ashburn, M.D., Ph.D., will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference on Monday, March 28, 2022 at 12:30 p.m. ET.
-
Oncorus to Present at the Oppenheimer 32nd Annual Healthcare Conference
3/10/2022
Oncorus, Inc. announced that President and Chief Executive Officer, Theodore Ashburn, M.D., Ph.D., will present at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 4:40 p.m. ET.
-
Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
3/9/2022
Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, reported fourth quarter and full year 2021 financial results and highlighted recent achievements and developments.
-
Oncorus Announces Promotion of John Goldberg, M.D. to Chief Medical Officer
2/22/2022
Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced the promotion of John Goldberg, M.D. to Chief Medical Officer.
-
Oncorus to Present at the H.C. Wainwright BioConnect Virtual Conference
1/3/2022
Oncorus, Inc. today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at the H.C. Wainwright BioConnect Conference.
-
Oncorus to Present at Upcoming Investor Conferences
11/23/2021
Oncorus, Inc. today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming virtual investor conferences: 33rd Annual Piper Sandler Virtual Healthcare Conference.